AVITA Medical, Inc.

NasdaqCM:RCEL Voorraadrapport

Marktkapitalisatie: US$337.3m

AVITA Medical Beheer

Beheer criteriumcontroles 2/4

De CEO AVITA Medical is Jim Corbett, benoemd in Sep2022, heeft een ambtstermijn van 2.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.07M, bestaande uit 30.2% salaris en 69.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.033% van de aandelen van het bedrijf, ter waarde $ 111.65K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 6.1 jaar.

Belangrijke informatie

Jim Corbett

Algemeen directeur

US$2.1m

Totale compensatie

Percentage CEO-salaris30.2%
Dienstverband CEO2.2yrs
Eigendom CEO0.03%
Management gemiddelde ambtstermijn1.8yrs
Gemiddelde ambtstermijn bestuur6.1yrs

Recente managementupdates

Recent updates

AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Oct 04
AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 11
AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Jul 18
AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?

Jun 18
Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?

Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding

Apr 12
Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding

AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39%

Feb 02
AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39%

The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32%

Oct 20
The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32%

Avita Medical appoints James Corbett as CEO

Sep 29

AVITA Medical says trial evaluating its RECELL system to treat vitiligo met main goal

Sep 12

Avita's burn therapy Recell gets insurance coverage in Japan following approval

Sep 01

AVITA Medical GAAP EPS of -$0.25 beats by $0.15, revenue of $8.34M beats by $1.18M

Aug 11

AVITA Medical Is Interesting, But Not Just Yet

Dec 21

AVITA Medical reports preliminary Q2 revenue in-line with consensus

Jan 12

AVITA: COVID-19's Impact

Nov 17

Analyse CEO-vergoeding

Hoe is Jim Corbett's beloning veranderd ten opzichte van AVITA Medical's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$57m

Jun 30 2024n/an/a

-US$50m

Mar 31 2024n/an/a

-US$45m

Dec 31 2023US$2mUS$625k

-US$35m

Sep 30 2023n/an/a

-US$34m

Jun 30 2023n/an/a

-US$31m

Mar 31 2023n/an/a

-US$26m

Dec 31 2022US$2mUS$157k

-US$27m

Sep 30 2022n/an/a

-US$30m

Jun 30 2022n/an/a

-US$30m

Mar 31 2022n/an/a

-US$29m

Dec 31 2021US$256kn/a

-US$25m

Compensatie versus markt: De totale vergoeding ($USD 2.07M ) Jim } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.12M ).

Compensatie versus inkomsten: De vergoeding van Jim is gestegen terwijl het bedrijf verliesgevend is.

CEO

Jim Corbett (66 yo)

2.2yrs

Tenure

US$2,068,675

Compensatie

Mr. James M. Corbett, also known as Jim, served as Chief Executive Officer of CathWorks Ltd. since October 27, 2017 until 2021. He serves as Director of CathWorks Ltd.until 2021. He served as an Independe...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
James Corbett
CEO, President & Executive Director2.2yrsUS$2.07m0.033%
$ 111.7k
David O'Toole
Chief Financial Officer1.4yrsUS$2.18mgeen gegevens
David Fencil
Senior Vice President of Global Operations1.8yrsgeen gegevensgeen gegevens
Katie Bush
Senior Vice President of Scientific & Medical Affairsless than a yeargeen gegevensgeen gegevens
Jessica Ekeberg
Investor Relations Executiveno datageen gegevensgeen gegevens
Nicole Kelsey
Chief Legal & Compliance Officer and Corporate Secretaryless than a yeargeen gegevensgeen gegevens
Debbie Garner
Senior Vice President of Global Marketing & Strategy6.3yrsgeen gegevensgeen gegevens
Rob Hall
Senior Vice President of Human Resources1.8yrsgeen gegevensgeen gegevens
Niraj Doshi
Senior Vice President of Product Development & Program Management1.8yrsgeen gegevensgeen gegevens
Ron Lagerquist
Senior Vice President of Quality Assurance & Regulatory Affairs1.8yrsgeen gegevensgeen gegevens
Robin VanDenburgh
Senior Vice President of U.S. Commercial Salesless than a yeargeen gegevensgeen gegevens

1.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van RCEL wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

NaamPositieTenureCompensatieEigendom
James Corbett
CEO, President & Executive Director3.3yrsUS$2.07m0.033%
$ 111.7k
Jan Reed
Independent Non-Executive Director3.3yrsUS$211.12k0.11%
$ 371.4k
Jeremy Curnock-Cook
Independent Non-Executive Director12.1yrsUS$199.87k0.079%
$ 264.9k
Fiona Wood
Founder and Member of Clinical Advisory Board8.8yrsUS$29.80kgeen gegevens
Louis Panaccio
Independent Non-Executive Chairman10.3yrsUS$234.69k0.16%
$ 554.9k
Robert McNamara
Independent Non-Executive Director1.6yrsUS$369.11k0.075%
$ 252.3k
Cary Vance
Independent Non-Executive Director1.6yrsUS$364.94k0.037%
$ 123.8k
Suzanne Crowe
Independent Non-Executive Director8.8yrsUS$195.28k0.10%
$ 349.9k

6.1yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RCEL wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.1 jaar).